无活动性肾炎的系统性红斑狼疮患者中，无证据表明血小板活化因子存在假定的参与作用。
No evidence for a putative involvement of platelet-activating factor in systemic lupus erythematosus without active nephritis.
作者信息
Denizot Yves, Liozon Eric, Guglielmi Laurence, Ly Kim, Soria Pascale, Loustaud Véronique, Vidal Elisabeth, Jauberteau Marie Odile
机构信息
UMR CNRS 6101, Laboratoire d'Immunologie, Faculté de Médecine, 2 rue Dr Marcland, 87025 Limoges, France.
出版信息
Mediators Inflamm. 2003 Apr;12(2):101-5. doi: 10.1080/0962935031000097718.
BACKGROUND
Platelet-activating factor (PAF) seems to be implicated in systemic lupus erythematosus (SLE) patients with associated renal diseases.
AIMS
In this study, we ensured the role of PAF in SLE patients without renal complications.
METHODS
Blood PAF and acetylhydrolase activity, plasma soluble phospholipase A(2), and the presence of antibodies against PAF were investigated in 17 SLE patients without active nephritis and in 17 healthy controls.
RESULTS
Blood PAF levels were not different (p=0.45) between SLE patients (6.7+/-2.8 pg/ml) and healthy subjects (9.6+/-3.1 pg/ml). Plasma acetylhydrolase activity (the PAF-degrading enzyme) was significantly (p=0.03) elevated in SLE patients (57.8+/-6.4 nmol/min/ml) as compared with controls (37.9+/-2.6 nmol/min/ml). Plasma soluble phospholipase A(2) (the key enzyme for PAF formation) was not different (p=0.6) between SLE patients (59.1+/-5.1 U/ml) and controls (54.7+/-2.4 U/ml). Antibodies against PAF were detected only in 3/17 SLE patients. Flow cytometry analysis did not highlight PAF receptors on circulating leukocytes of SLE patients.
CONCLUSION
This clinical study highlights no evidence for a putative important role of PAF in SLE patients without active nephritis.
背景
血小板活化因子（PAF）似乎与患有相关肾脏疾病的系统性红斑狼疮（SLE）患者有关。
目的
在本研究中，我们确定了PAF在无肾脏并发症的SLE患者中的作用。
方法
对17例无活动性肾炎的SLE患者和17名健康对照者进行了血液PAF和乙酰水解酶活性、血浆可溶性磷脂酶A2以及抗PAF抗体的检测。
结果
SLE患者（6.7±2.8 pg/ml）和健康受试者（9.6±3.1 pg/ml）的血液PAF水平无差异（p=0.45）。与对照组（37.9±2.6 nmol/min/ml）相比，SLE患者（57.8±6.4 nmol/min/ml）的血浆乙酰水解酶活性（PAF降解酶）显著升高（p=0.03）。SLE患者（59.1±5.1 U/ml）和对照组（54.7±2.4 U/ml）的血浆可溶性磷脂酶A2（PAF形成的关键酶）无差异（p=0.6）。仅在3/17的SLE患者中检测到抗PAF抗体。流式细胞术分析未发现SLE患者循环白细胞上有PAF受体。
结论
这项临床研究没有发现PAF在无活动性肾炎的SLE患者中起假定重要作用的证据。
Zotero 插件